Literature DB >> 26899817

Melancholic features in inpatients with major depressive disorder associate with differential clinical characteristics and treatment outcomes.

Ching-Hua Lin1, Chun-Jen Huang2, Shi-Kai Liu3.   

Abstract

To determine whether the presence of melancholic features in hospitalized patients with major depressive disorder (MDD) was associated with specific clinical characteristics and treatment outcomes, supporting melancholic depression as a distinct subtype within MDD. 126 acutely ill inpatients with MDD were enrolled in an open, 6-week trial with fixed-dose fluoxetine 20mg daily. Symptom severity was assessed regularly, using the 17-item Hamilton Depression Rating Scale (HAMD-17) and Clinical Global Impression of Severity (CGI-S). Melancholic features were defined according to the DSM-IV criteria. Clinical variables were compared between patients with and without melancholic features. Generalized estimating equations method was used to explore the differences in HAMD-17 and CGI-S scores between the 2 groups over time. Clinical response was defined as having a 50% or greater reduction in HAMD-17 scores. 96 (76.2%) of the 126 patients with at least one post-baseline assessment met the criteria for melancholic depression. Melancholic depression differed from non-melancholic depression in clinical characteristics and predicted a better response to fluoxetine treatment. The differentiation between melancholic and non-melancholic depression within MDD hence is clinically significant and valid.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Fluoxetine; Generalized estimating equations; Major depressive disorder; Melancholic

Mesh:

Substances:

Year:  2015        PMID: 26899817     DOI: 10.1016/j.psychres.2015.11.009

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

1.  Editorial Comment: Stress and Late-Life Depression.

Authors:  Christopher C Abbott; Mohamad Khafaja
Journal:  Am J Geriatr Psychiatry       Date:  2017-05-17       Impact factor: 4.105

2.  The Developmental and Translational Study on Biomarkers and Clinical Characteristics-based Diagnostic and Therapeutic Identification of Major Depressive Disorder: Study Protocol for a Multicenter Randomized Controlled Trial in China.

Authors:  Xiaohua Liu; Yun Wang; Huifeng Zhang; Daihui Peng; Yanqun Zheng; Yan Wu; Yun-Ai Su; Ming Liu; Xiancang Ma; Yi Li; Jianfei Shi; Xiaojing Cheng; Han Rong; Yiru Fang
Journal:  Neuropsychiatr Dis Treat       Date:  2020-10-09       Impact factor: 2.570

3.  Medium- and high-intensity rTMS reduces psychomotor agitation with distinct neurobiologic mechanisms.

Authors:  Alesha Heath; Daniel R Lindberg; Kalina Makowiecki; Avalon Gray; Anders J Asp; Jennifer Rodger; Doo-Sup Choi; Paul E Croarkin
Journal:  Transl Psychiatry       Date:  2018-07-05       Impact factor: 6.222

4.  The Gender-Specific Interaction of DVL3 and GSK3β Polymorphisms on Major Depressive Disorder Susceptibility in a Chinese Han Population: A Case-Control Study.

Authors:  Siyuan Ke; Jiarui Li; Lu Zhao; Jiarun Yang; Xueyan Zhao; Wenxin Zhang; Xiaohui Qiu; Xiuxian Yang; Jiawei Zhou; Yuying Tong; Xiongzhao Zhu; Xuan Liu; Yanjie Yang; Zhengxue Qiao; Tianyi Bu
Journal:  Oxid Med Cell Longev       Date:  2022-01-28       Impact factor: 6.543

5.  The establishment of the objective diagnostic markers and personalized medical intervention in patients with major depressive disorder: rationale and protocol.

Authors:  Xiaozhen Lv; Tianmei Si; Gang Wang; Huali Wang; Qi Liu; Changqing Hu; Jing Wang; Yunai Su; Yu Huang; Hui Jiang; Xin Yu
Journal:  BMC Psychiatry       Date:  2016-07-15       Impact factor: 3.630

6.  Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder.

Authors:  Nadine Dreimüller; Stefanie Wagner; Alice Engel; Dieter F Braus; Sibylle C Roll; Stefan Elsner; André Tadić; Klaus Lieb
Journal:  BMC Psychiatry       Date:  2019-01-14       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.